title: Lipid testing and lipid-lowering therapy in hospitalized ischemic stroke and transient ischemic attack patients: results from a statewide stroke registry.
abstract: OBJECTIVE
  Recent recommendations call for in-hospital initiation of lipid-lowering therapy (LLT) for most ischemic stroke (IS) and transient ischemic attack (TIA) survivors; however, little is known about actual use. This study describes use of and predictors for in-hospital lipid testing and LLT using data from a statewide stroke registry.
  
  
  METHODS
  In 2002, the registry ascertained cases from a stratified sample of 16 hospitals. This study includes only IS and TIA cases discharged alive.
  
  
  RESULTS
  In 1907 study subjects, 30.2% (27.2% to 33.5%) were on LLT at admission. In 1399 subjects not on LLT at admission, 37.2% (30.2% to 44.9%) underwent lipid testing, and 12.9% (7.2% to 22.1%) received LLT at discharge. Use of testing and LLT varied widely between hospitals (P<0.001). In-hospital lipid testing was positively associated with large teaching hospitals (P=0.029), and neurologist or neurosurgeon (P=0.004); and negatively associated with increasing age (P=0.002), being female (P=0.020), a previous medical history of atrial fibrillation (P=0.002), nonambulatory status (P=0.005), and poor prognosis (P<0.001). LLT at discharge was positively associated with a previous medical history of dyslipidemia (P<0.001), lipid testing (P=0.004), and elevated low-density lipoprotein levels (P<0.001). Among subjects who were not on LLT at admission but who had Adult Treatment Panel III-based indications for use of LLT, only 31.2% (20.5% to 44.5%) received LLT at discharge.
  
  
  CONCLUSIONS
  Many hospitalized acute IS and TIA patients with indications for LLT are untreated at discharge. Efforts to close treatment gaps in lipid evaluation and treatment require sustained quality improvement efforts and should pay particular attention to high-risk patients.
authors.affiliation: Department of Epidemiology, Michigan State University, East Lansing, MI 48824, USA.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Mullard
authors.forename: Mathew J
authors.initials: MJ
authors.lastname: Reeves
authors.forename: Bradley S
authors.initials: BS
authors.lastname: Jacobs
authors.forename: Rashmi U
authors.initials: RU
authors.lastname: Kothari
authors.forename: Gretchen L
authors.initials: GL
authors.lastname: Birbeck
authors.forename: Kate
authors.initials: K
authors.lastname: Maddox
authors.forename: Stacey
authors.initials: S
authors.lastname: Stoeckle-Roberts
authors.forename: Susan
authors.initials: S
authors.lastname: Wehner
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002995:Clofibric Acid / Q000627:therapeutic use; D005260:Female; D006753:Hospital Records; D006760:Hospitalization; D006761:Hospitals; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007511:Ischemia / Q000175:diagnosis* / Q000628:therapy; D002546:Ischemic Attack, Transient / Q000175:diagnosis* / Q000628:therapy; D008055:Lipids / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D009525:Niacin / Q000627:therapeutic use; D012042:Registries; D012307:Risk Factors; D020521:Stroke / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy
chemical_list: D000925:Anticoagulants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D002792:Cholestyramine Resin; D009525:Niacin; D002995:Clofibric Acid